Insulin and Blood Sugar in Children: Dosing, Targets, and Special Populations

How Blood Sugar Regulation Works in Children

Children's glucose physiology differs from adults in several measurable ways, and those differences affect every insulin decision a clinician makes. The pediatric pancreas secretes insulin in response to meals and suppresses glucagon during the fed state, just as in adults, but counter-regulatory hormone responses are often more pronounced in younger children, making hypoglycemia both more common and more dangerous. The brain of a child under six accounts for a disproportionately large share of total glucose consumption, which is why severe or prolonged hypoglycemia in early childhood can impair neurocognitive development [1].

Growth hormone surges during puberty drive substantial insulin resistance. A 13-year-old girl in mid-puberty may need 30 to 50% more total daily insulin (TDI) than she required at age 10, even without any change in diet or activity [2]. Recognizing this pattern allows clinicians to anticipate dose increases rather than react to unexplained hyperglycemia.

The ADA's 2024 Standards of Medical Care in Diabetes state: "An HbA1c goal of <7% (53 mmol/mol) is appropriate for many children and adolescents if it can be achieved without excessive hypoglycemia" [3]. That caveat about hypoglycemia is not a formality. Severe hypoglycemia rates in children with type 1 diabetes (T1D) run as high as 19 episodes per 100 patient-years in some registry data [4].

Continuous glucose monitoring (CGM) has changed pediatric diabetes management more than any single pharmacologic advance. The ISPAD 2022 Clinical Practice Consensus Guidelines endorse CGM as the preferred monitoring method for all children with T1D on insulin [5]. Time in range (TIR), defined as the percentage of readings between 70 and 180 mg/dL, is now a co-primary endpoint alongside HbA1c in pediatric trials. A TIR above 70% correlates with an HbA1c near 7% and is the current clinical benchmark [6].

Insulin Regimens for Pediatric Type 1 Diabetes

Basal-bolus therapy is the standard of care for children with T1D, and closed-loop systems are rapidly becoming the preferred delivery method. A child with T1D generally starts with a TDI of 0.5, 0.7 units/kg/day at diagnosis, split roughly 50% basal and 50% bolus [3]. During the partial remission phase (the "honeymoon"), TDI may drop below 0.5 units/kg/day; during puberty it can climb to 1.0, 1.5 units/kg/day [2].

Insulin detemir (Levemir) and insulin glargine U-100 (Lantus) both carry FDA approval for children aged two years and older [7]. Insulin degludec (Tresiba) is approved for adults and some pediatric populations; the SWITCH PRO trial demonstrated lower rates of confirmed hypoglycemia with degludec compared to glargine U-100 in adults, a finding that influenced off-label use in older children and adolescents [8].

Rapid-acting analogs used for meal coverage in children include insulin lispro (Humalog), insulin aspart (NovoLog), and insulin glulisine (Apidra). Faster insulin aspart (Fiasp) showed a 1.8 mg/dL lower mean glucose in the onset 7 pediatric trial compared to standard aspart, with no significant difference in hypoglycemia rates [9].

Closed-loop systems (automated insulin delivery, AID) are particularly valuable for children because they adjust basal insulin in real time using CGM data. The CREATE trial (N=97, ages 7, 25) showed that the Android APS open-source system increased TIR by 14 percentage points compared to sensor-augmented pump therapy over 24 weeks [10]. Commercial systems such as the Omnipod 5 and Tandem Control-IQ have demonstrated similar gains in pediatric-specific subgroup analyses [11].

Practical Pediatric Insulin Initiation Framework (HealthRX Clinical Decision Tool)

| Age Group | Starting TDI | Preferred Basal | Basal:Bolus Split | HbA1c Target | |---|---|---|---|---| | 2 to 5 years | 0.3, 0.5 u/kg/day | Detemir or Glargine U-100 | 40:60 | <7.5% | | 6 to 11 years | 0.5, 0.7 u/kg/day | Detemir or Glargine U-100 | 50:50 | <7% | | 12 to 17 years | 0.7, 1.0 u/kg/day | Degludec or Glargine U-300 | 50:50 | <7% |

Carbohydrate ratios typically start at 1 unit per 15 g in young children and tighten to 1 unit per 8 to 10 g in insulin-resistant adolescents. Correction factors follow the "1800 rule" for rapid analogs (1800 divided by TDI gives the expected glucose drop in mg/dL per unit) [3].

Blood Sugar Management During Pregnancy

Pregnancy imposes unique glucose demands regardless of whether diabetes preceded conception or developed during gestation. Women with pregestational T1D or type 2 diabetes (T2D) entering pregnancy should target an HbA1c below 6.5% if achievable without hypoglycemia, according to the 2024 ADA Standards [3]. Tighter targets below 6% may lower fetal macrosomia risk but sharply increase maternal hypoglycemia episodes.

Gestational diabetes mellitus (GDM) glucose targets recommended by ACOG are: fasting <95 mg/dL, one-hour postprandial <140 mg/dL, and two-hour postprandial <120 mg/dL [12]. Roughly 15 to 20% of women with GDM require insulin to meet those targets after 1 to 2 weeks of nutrition therapy. NPH insulin is the most studied agent in this context, and FDA labeling supports its use in pregnancy. Insulin glargine U-100 has a reassuring safety profile from observational data, though it lacks the same volume of randomized trial evidence [13].

Insulin requirements change dramatically across trimesters. First-trimester requirements often drop due to nausea and reduced food intake. By the third trimester, placental hormones drive insulin resistance to a level that can double or triple the preconception dose. This escalation is physiologic and expected. Women on insulin pumps typically need aggressive basal rate increases between weeks 28 and 36 [3].

Postpartum, insulin sensitivity rebounds within hours of delivery. Women with T1D commonly experience severe hypoglycemia in the 24 hours after birth, and their insulin doses should be preemptively reduced by 30 to 50% at delivery [3].

Insulin and Blood Sugar in Older Adults

Older adults present a genuinely distinct risk profile for insulin therapy. Hypoglycemia in this population carries consequences that go well beyond discomfort: a single severe episode is associated with a two-fold increase in dementia risk in some cohort analyses [14]. The ADA and American Geriatrics Society both recommend less aggressive HbA1c targets for older adults with functional limitations, multiple comorbidities, or limited life expectancy, typically 7.5 to 8.5% [3].

Physiologic changes affecting insulin pharmacokinetics in older adults include reduced renal clearance of insulin and its metabolites, decreased counter-regulatory hormone responses, impaired hypoglycemia awareness, and altered subcutaneous absorption due to changes in adipose tissue distribution. Basal insulin analogs with flat, predictable activity curves (degludec, glargine U-300) are preferred over NPH, which has a pronounced peak that raises hypoglycemia risk, especially overnight [8].

Polypharmacy is a compounding factor. Beta-blockers mask the tachycardia that typically alerts a patient to hypoglycemia. Fluoroquinolone antibiotics can cause unpredictable glucose swings. Corticosteroids for arthritis or COPD exacerbations cause postprandial hyperglycemia that may require supplemental rapid-acting insulin on a sliding scale [3].

Simplified regimens perform better in older adults who have cognitive impairment or limited caregiver support. A once-daily basal insulin with or without a single premixed dose at the largest meal is often safer than a full basal-bolus regimen with four daily injections [15].

Insulin Dosing in Chronic Kidney Disease and Renal Disease

The kidney contributes 25 to 40% of total insulin clearance in healthy adults, so declining eGFR directly prolongs insulin action and raises hypoglycemia risk [16]. At eGFR 30 to 60 mL/min/1.73m², total daily insulin requirements may fall by 25%. At eGFR <30 mL/min/1.73m², reductions of 50% or more are sometimes necessary [16].

Regular insulin (Humulin R, Novolin R) is cleared primarily by the kidney and accumulates substantially in advanced CKD. Rapid-acting analogs are partly hepatically metabolized and may behave more predictably in moderate CKD, though prospective head-to-head data in this specific population are limited [16]. Dialysis sessions themselves alter glucose: hemodialysis with glucose-containing dialysate raises blood sugar; sessions with low-glucose dialysate can precipitate hypoglycemia.

Diabetic kidney disease (DKD) is present in approximately 40% of people with T1D and 20 to 30% of those with T2D [17]. For patients with DKD and T2D, the combination of an SGLT2 inhibitor and a GLP-1 receptor agonist reduces albuminuria and cardiovascular risk independent of insulin, which is relevant because it may allow insulin dose reduction over time [17]. The CREDENCE trial (N=4,401) demonstrated that canagliflozin reduced the composite of kidney failure, doubling of serum creatinine, and renal or cardiovascular death by 30% in T2D patients with DKD, a finding that reshapes the insulin-centric management approach for this population [18].

Target HbA1c in CKD is complicated by the fact that HbA1c underestimates true glycemia in patients with anemia or after blood transfusions, both common in advanced renal disease. Fructosamine or glycated albumin may be more reliable glycemic markers in this setting [16].

Insulin and Blood Sugar in Heart Failure

Heart failure and diabetes co-exist in 25 to 40% of patients with either condition [19]. The metabolic relationship is bidirectional: chronic hyperglycemia damages the myocardium through advanced glycation end-products and oxidative stress, while heart failure itself promotes insulin resistance through neurohormonal activation and reduced skeletal muscle perfusion.

Hypoglycemia is the immediate danger to monitor in this population. A single episode of severe hypoglycemia triggers a catecholamine surge that raises heart rate, prolongs the QT interval, and may precipitate ventricular arrhythmias. Among patients with T2D and established cardiovascular disease, severe hypoglycemia was associated with a hazard ratio of 2.69 for subsequent cardiovascular death in the ACCORD trial sub-analysis [20].

Insulin is generally necessary in patients with heart failure and T1D or advanced T2D, but the regimen should minimize hypoglycemia above all other goals. Glucose targets for heart failure patients are typically liberalized to an HbA1c of 7.5 to 8% unless the patient is otherwise young and well-compensated [3]. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become first-line agents in heart failure with reduced ejection fraction (HFrEF) regardless of diabetes status, based on the DAPA-HF trial (N=4,744), which showed dapagliflozin reduced the composite of worsening heart failure or cardiovascular death by 26% compared to placebo [21]. Adding an SGLT2 inhibitor to insulin in this population may allow modest insulin dose reduction due to the drug's glycosuric effect, but it also requires careful monitoring for volume depletion in patients already on diuretics [21].

Thiazolidinediones are contraindicated in heart failure due to fluid retention. Metformin use in heart failure was historically discouraged but is now considered acceptable in stable patients with eGFR above 30 mL/min/1.73m², per updated ADA guidance [3]. Neither of these directly displaces insulin in the T1D population with heart failure, but they inform the multi-drug regimen that surrounds insulin therapy.

Monitoring and Safety Across All Populations

CGM improves outcomes across every population discussed in this article. The CONCEPTT trial (N=325) demonstrated that CGM use in pregnant women with T1D was associated with significantly more time in range (68% vs. 61%, P<0.001) and lower rates of neonatal intensive care unit admissions compared to standard glucose monitoring [22]. That 7-percentage-point TIR difference translated into 62 fewer infants requiring NICU care per 1,000 deliveries, a clinically meaningful absolute difference.

Hypoglycemia awareness training programs such as BGAT (Blood Glucose Awareness Training) reduce severe hypoglycemia rates by approximately 50% over 12 months in adults with T1D [23]. Similar structured education programs adapted for parents of young children with T1D, such as PRISM (Problem Recognition in Situations at Risk of hypoglycemia with their child's basal Monitoring), show comparable benefits in the pediatric caregiver setting [4].

Sick-day management rules are non-negotiable for children and older adults on insulin. During febrile illness, insulin requirements often increase by 20 to 30% even if food intake drops, because counter-regulatory hormones drive hepatic glucose output. Holding insulin during illness is a common and dangerous error; the standard guidance is to continue basal insulin at full dose and monitor blood glucose every 2 to 3 hours [3].

Insulin storage affects potency. Insulin in current use can be kept at room temperature (below 77°F / 25°C) for 28 days. Insulin exposed to temperatures above 86°F (30°C) loses significant biological activity within hours [7]. This matters for children in school settings and older adults in poorly climate-controlled housing.